 pharmacokinet patient aid aids-rel complex tetrahydroimidazobenzodiazepinthion tibo potent activ human immunodefici viru vitro patient aid aids-rel complex dose-escal pilot studi dose mg intraven infus week haematolog biochem evid toxic mean cell count second month treatment steady-st plasma concentr drug median antigen concentr first month therapi rise antigen therapi fall treatment end-point analysi signific differ combin potent antiretrovir activ vitro observ effect hiv antigen absenc toxic vivo indic relat tibo deriv studi treatment retrovir infect